Liu A, Williams LE, Wong JYC, Raubitschek AA. Monte Carlo assisted voxel source kernel method (MAVSK) for internal dosimetry. Journal of Nuclear Medicine and Biology 1998;25: 423-33.
Clarke KG, Odom-Maryon TL, Williams LE, Liu A, Lopatin G, Chou J, Farino GM, Raubitschek AA. Wong JYC. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy. Med Phys 1999;26: 799-809.
Liu A, Williams LE, Lopatin G, Wong JYC, Raubitschek AA. RTDS – A radionuclide therapy treatment planning and dose estimation system. J Nuc Med. 1999;40: 1151-53.
Wu AM, Yazaki PJ, Tsai SW, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JYC, Toyokuni T, Phelps ME, and Gambhir SS. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a Copper-64-labeled engineered antibody fragment”. Proc Nat Acad Sci 2000;97:8495-00.
Williams LE. Clinical results and the necessity of estimating patient-specific radiation absorbed dose in radioimmunotherapy. Cancer Biotherapy and Radiopharm 2000;15:301-303
Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000;60:4475-84.
Yazaki PJ, Wu AM, Tsai SH, Williams LE, Ikle DN, Wong JYC, Shively JE, Raubitschek AA. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments. Bioconjugate Chem 2001;12: 220-8.
Williams LE, Wu AM, Yazaki PJ, Liu A, Raubitschek AA, Shively JE, Wong JYC. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biotherapy and Radiopharm 2001; 16:25-35.
Macey DJ, Williams LE, Breitz HB, Liu A, Johnson TK, Zanzonico PB. A Primer for Radioimmunotherapy and Radionuclide Therapy. AAPM Report No. 71, Medical Physics Publishing, Madison WI, 2001, pp. i-vii and 1-68.
Williams LE, Beatty BG, Shively JE and Beatty JD. Accumulation of radiolabeled anti-CEA antibody (mT84.66) in the case of multiple LS174T tumors in a nude mouse model. Cancer Biotherapy and Radiopharm 2001;16: 147-57.
Holdsworth CH, Dahlbom M, Liu A, Williams L, Levin CS, Janecek M, Hoffman EJ. Expanding the versatility of a more accurate accelerated Monte Carlo simulation for 3D PET: Data correction of PET emission Scans using 124-I. Nuclear Science Symposium Conference Record, 2001 IEEE 2002;4: 2105-09.
Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. Iodine-124 labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific, small Animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-69.
Wong JYC, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A phase I trial of 90-Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin.Cancer Res 2003;9: 5842-52.
Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Prot. Eng. Design and Selection 2004;17: 1-7.
Williams L, Liu A, Wu A,Yamauchi D, Lopatin G, Yazaki P, Raubitschek A, Wong J. Verification of imaging figure of merit as a predictor of tumor imaging clarity. Proceedings of the World congress on Medical Physics and Biomedical Engineering, August 24-29, 2003, Sydney Australia, [CD-ROM] ISBN 1877040142, Paper 737, 4 pages.
Wong JYC , Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA. A pilot trial evaluating a 123-I-labeled 80 kD engineered anti-CEA antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Can Research 2004;10: 5014-21.
Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JYC, Colcher D, Wu AM, Raubitschek AA. Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Prot Eng Design and Selection 2004;17: 481-9.
Olafsen T, Tan , C.-W. Cheung, P.J. Yazaki, J.M. Park, J.E. Shively, L.E. Williams, A.A. Raubitschek , M. F. Press, and A.M. Wu: “ Characterization of Engineered anti-p185 HER-2 (scFv-CH3)2 Antibody Fragments (Minibodies) for Tumor Targeting”. Prot. Eng. Design & Selection 17: 315-323, 2004.
Kenanova V, Olafsen T, Crow D, Sundaresan G, Subbarayan M, Carter N, Ikle D, Yazaki P, Chatziioannou A, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM. Tailoring the pharmacokinetics of engineered antibody fragments. Biodistribution and small animal PET imaging of anti-CEA scFv-Fc and variants. Cancer Res.2005;65: 622-31.
Olafsen T, Kenanova V, Sundaresan G, Anderson AL, Crow D, Li L, Press M, Gambhir SS, Williams LE, Wong JYC, Raubitschek AA, Shively JE, Wu AM. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res.2005;65:5907-16.
Crow DM, Williams LE, Colcher D, Wong JY, Raubitschek AA, Shively JE. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90 labeled anti-HER2 and anti-CEA antibodies with taxol. Bioconjugate Chem.2005;16:1117-25.
Madsen MT, Anderson JA, Halama JR, Kleck J, Simpkin DJ, Votaw JR, Wendt RE, Williams LE, Yester MV. AAPM Task Group 108: PET and PET/CT shielding requirements. Med Phys 2006;33:4-15.
Wong JYC, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA: A phase I trial of Y-90-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biotherapy and Radiopharm 2006;21:88-100.
Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JYC, Raubitschek AA, Shively JE. Improved biodistribution and radioimmunoimaging with polyethylene glycol-DOTA conjugated anti-CEA diabody. Bioconjugate Chem 2006;17: 68-76.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.
